Who
Carl Dambkowski
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Apogee Therapeutics; Director, Oruka Therapeutics.
In numbers
- Trades disclosed
- 165
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $39.5M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 18 Dec 2023
- Last trade
- 3 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —167,123 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —110,665 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —110,665 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —124,962 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —83,690 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —124,962 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —83,690 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | —167,123 | filing |
| 2 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | $186K1,375 at $135.06 | filing |
| 2 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | $186K1,375 at $135.06 | filing |
| 5 Aug 2026filed 7 Aug 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code M | $94K4,125 at $22.86 | filing |
| 5 Aug 2026filed 7 Aug 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $738K5,500 at $134.17 | filing |
| 5 Aug 2026filed 7 Aug 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,125 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,125 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code M | $94K4,125 at $22.86 | filing |
| 5 Aug 2026filed 7 Aug 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $738K5,500 at $134.17 | filing |
| 14 Jul 2026filed 16 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code G | —8,000 at $0.00 | filing |
| 14 Jul 2026filed 16 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code G | —8,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code M | $94K4,125 at $22.86 | filing |
| 1 Jul 2026filed 2 Jul 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Sold | $730K5,500 at $132.74 | filing |
News
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026ORKA · manilatimes.net · 25 Oct 2026
0 headlines in the last 90 days name Carl Dambkowski; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.